• 29. März 2024

Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting

ByAnergis SA

Feb 23, 2015
#8722 Contiguous Overlapping Peptide allergy immunotherapeutic AllerT confirms sustained efficacy in the second year following treatment
Teile den Beitrag mit Freunden

http://www.news4press.com/News/Rubrik.asp weiter lesen

Kommentar verfassen

Booking.com